{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:20:23Z","timestamp":1788848423382,"version":"build-2803163510"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The highly pathogenic avian influenza H5N1 viruses constantly evolve and give rise to novel variants that have caused widespread zoonotic outbreaks and sporadic human infections. Therefore, vaccines capable of eliciting broadly protective antibody responses are desired and under development. We here investigated the magnitude, kinetics and protective efficacy of the multi-faceted humoral immunity induced by vaccination in healthy adult volunteers with a Matrix M adjuvanted virosomal H5N1 vaccine. Vaccinees were given escalating doses of adjuvanted vaccine (1.5\u03bcg, 7.5\u03bcg, or 30\u03bcg), or a non-adjuvanted vaccine (30\u03bcg). An evaluation of sera from vaccinees against pseudotyped viruses covering all (sub)clades isolated from human H5N1 infections demonstrated that the adjuvanted vaccines (7.5\u03bcg and 30\u03bcg) could elicit rapid and robust increases of broadly cross-neutralizing antibodies against all clades. In addition, the adjuvanted vaccines also induced multifaceted antibody responses including hemagglutinin stalk domain specific, neuraminidase inhibiting, and antibody-dependent cellular cytotoxicity inducing antibodies. The lower adjuvanted dose (1.5\u00b5g) showed delayed kinetics, whilst the non-adjuvanted vaccine induced overall lower levels of antibody responses. Importantly, we demonstrate that human sera post vaccination with the adjuvanted (30\u03bcg) vaccine provided full protection against a lethal homologous virus challenge in mice. Of note, when combining our data from mice and humans we identified the neutralizing and neuraminidase inhibiting antibody titers as correlates of <jats:italic>in vivo<\/jats:italic> protection.<\/jats:p>","DOI":"10.3389\/fimmu.2021.747774","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:32:31Z","timestamp":1638275551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection"],"prefix":"10.3389","volume":"12","author":[{"given":"Fan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnveig","family":"Gr\u00f8deland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"B1","unstructured":"Cumulative Number of Confirmed Human Cases for Avian Influenza A(H5N1) Reported to WHO, 2003-20212021"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0707279","article-title":"Update on Avian Influenza A (H5N1) Virus Infection in Humans","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"B3","article-title":"Antigenic and Genetic Characteristics of Zoonotic Influenza Viruses and Development of Candidate Vaccine Viruses for Pandemic Preparedness","volume":"89","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052211","article-title":"Avian Influenza A (H5N1) Infection in Humans","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.virusres.2013.05.006","article-title":"H5N1 Vaccines in Humans","volume":"178","author":"Baz","year":"2013","journal-title":"Virus Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau2710","article-title":"Prolonged Evolution of the Memory B Cell Response Induced by a Replicating Adenovirus-Influenza H5 Vaccine","volume":"4","author":"Matsuda","year":"2019","journal-title":"Sci Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1414070111","article-title":"Induction of Broadly Cross-Reactive Antibody Responses to the Influenza HA Stem Region Following H5N1 Vaccination in Humans","volume":"111","author":"Ellebedy","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and Immunogenicity of Influenza A H5 Subunit Vaccines: Effect of Vaccine Schedule and Antigenic Variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu123","article-title":"A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response","volume":"209","author":"Talaat","year":"2014","journal-title":"J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"10432","DOI":"10.1038\/s41598-018-28706-1","article-title":"The Influenza Virus Hemagglutinin Head Evolves Faster Than the Stalk Domain","volume":"8","author":"Kirkpatrick","year":"2018","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coi.2018.03.025","article-title":"Neuraminidase as an Influenza Vaccine Antigen: A Low Hanging Fruit, Ready for Picking to Improve Vaccine Effectiveness","volume":"53","author":"Eichelberger","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.11.006","article-title":"Emerging From the Shadow of Hemagglutinin: Neuraminidase Is an Important Target for Influenza Vaccination","volume":"26","author":"Krammer","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","article-title":"Characterization of Temperature Sensitive Influenza Virus Mutants Defective in Neuraminidase","volume":"61","author":"Palese","year":"1974","journal-title":"Virology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84428","article-title":"Broadly Neutralizing Anti-Influenza Antibodies Require Fc Receptor Engagement for","volume":"126","author":"DiLillo","year":"2016","journal-title":"Vivo Protect J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3443","article-title":"Broadly Neutralizing Hemagglutinin Stalk\u2013Specific Antibodies Require Fc\u03b3R Interactions for Protection Against Influenza Virus In Vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a Virosomal H5N1 Vaccine Formulated With Matrix M Adjuvant in a Phase I Clinical Trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131652","article-title":"Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection From Highly Pathogenic Influenza Challenge in Ferrets","volume":"10","author":"Cox","year":"2015","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29583","article-title":"Matrix M(TM) Adjuvanted Virosomal H5N1 Vaccine Induces Balanced Th1\/Th2 CD4(+) T Cell Responses in Man","volume":"10","author":"Pedersen","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.08.056","article-title":"Measurement of Neutralizing Antibody Responses Against H5N1 Clades in Immunized Mice and Ferrets Using Pseudotypes Expressing Influenza Hemagglutinin and Neuraminidase","volume":"27","author":"Tsai","year":"2009","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06930-11","article-title":"A Triclade DNA Vaccine Designed on the Basis of a Comprehensive Serologic Study Elicits Neutralizing Antibody Responses Against All Clades and Subclades of Highly Pathogenic Avian Influenza H5N1 Viruses","volume":"86","author":"Zhou","year":"2012","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/npjvaccines.2016.1","article-title":"Dissecting the Hemagglutinin Head and Stalk-Specific IgG Antibody Response in Healthcare Workers Following Pandemic H1N1 Vaccination","volume":"1","author":"Tete","year":"2016","journal-title":"NPJ Vaccines"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12801","article-title":"Functional Immune Response to Influenza H1N1 in Children and Adults After Live Attenuated Influenza Virus Vaccination","volume":"90","author":"Islam","year":"2019","journal-title":"Scand J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15G.1.1","DOI":"10.1002\/0471729256.mc15g01s3","article-title":"Influenza: Propagation, Quantification, and Storage","volume":"3","author":"Szretter","year":"2006","journal-title":"Curr Protoc Microbiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn180","article-title":"Phylogeny.fr: Robust Phylogenetic Analysis for the Non-Specialist","volume":"36","author":"Dereeper","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz303","article-title":"NGPhylogeny.fr: New Generation Phylogenetic Services for Non-Specialists","volume":"47","author":"Lemoine","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B26","first-page":"88","article-title":"Antigenic and Genetic Characteristics of Zoonotic Influenza A Viruses and Development of Candidate Vaccine Viruses for Pandemic Preparedness","volume":"96","year":"2021","journal-title":"Wkly Epidemiol Rec"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen Sparing and Cross-Reactive Immunity With an Adjuvanted Rh5n1 Prototype Pandemic Influenza Vaccine: A Randomised Controlled Trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001665","article-title":"Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 Rh5n1 Pandemic Influenza Vaccine","volume":"3","author":"Leroux-Roels","year":"2008","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.05.077","article-title":"Phase I and II Randomised Trials of the Safety and Immunogenicity of a Prototype Adjuvanted Inactivated Split-Virus Influenza A (H5N1) Vaccine in Healthy Adults","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.08.046","article-title":"Safety and Immunogenicity of a Prototype Adjuvanted Inactivated Split-Virus Influenza A (H5N1) Vaccine in Infants and Children","volume":"26","author":"Nolan","year":"2008","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01340-17","article-title":"A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice Against H7 Influenza","volume":"91","author":"Andersen Tor","year":"2017","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1016\/j.vaccine.2009.07.079","article-title":"Pseudoparticle Neutralization Is a Reliable Assay to Measure Immunity and Cross-Reactivity to H5N1 Influenza Viruses","volume":"27","author":"Alberini","year":"2009","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129520","article-title":"Selective Induction of Antibody Effector Functional Responses Using MF59-Adjuvanted Vaccination","volume":"130","author":"Boudreau","year":"2020","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.25","article-title":"ISCOM Technology-Based Matrix M Adjuvant: Success in Future Vaccines Relies on Formulation","volume":"10","author":"Lovgren Bengtsson","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.028","article-title":"Safety and Immunogenicity of Heterologous Prime-Boost Immunization With Viral-Vectored Malaria Vaccines Adjuvanted With Matrix-M\u2122","volume":"35","author":"Venkatraman","year":"2017","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a Low-Dose Candidate Malaria Vaccine, R21 in Adjuvant Matrix-M, With Seasonal Administration to Children in Burkina Faso: A Randomised Controlled Trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1017\/s0022172400022610","article-title":"The Role of Serum Haemagglutination-Inhibiting Antibody in Protection Against Challenge Infection With Influenza A2 and B Viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J Hyg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02133-14","article-title":"Induction of Broadly Reactive Anti-Hemagglutinin Stalk Antibodies by an H5N1 Vaccine in Humans","volume":"88","author":"Nachbagauer","year":"2014","journal-title":"J Virol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01463-17","article-title":"Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum Are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model","volume":"8","author":"Jacobsen","year":"2017","journal-title":"mBio"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00417-16","article-title":"Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A\/H1N1 Virus Healthy Human Challenge Model","volume":"7","author":"Memoli","year":"2016","journal-title":"mBio"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody Correlates and Predictors of Immunity to Naturally Occurring Influenza in Humans and the Importance of Antibody to the Neuraminidase","volume":"207","author":"Couch","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection","volume":"212","author":"Monto","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12706","article-title":"Meeting Report and Review: Immunological Assays and Correlates of Protection for Next-Generation Influenza Vaccines","volume":"14","author":"Krammer","year":"2020","journal-title":"Influenza Other Respir Viruses"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.747774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:32:34Z","timestamp":1638275554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.747774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2021.747774"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.747774","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"article-number":"747774"}}